Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. - Wikidata - wikimedia - TriplyDB

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

http://www.wikidata.org/entity/Q34016504

about

Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes New insights into the role of EMT in tumor immune escape.TGFβ in T cell biology and tumor immunity: Angel or devil?Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.Killer Immunoglobulin-like Receptors (KIR) haplogroups A and B track with Natural Killer Cells and Cytokine Profile in Aged Subjects: Observations from Octo/Nonagenarians in the Belfast Elderly Longitudinal Free-living Aging STudy (BELFAST).The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity.Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation Ovarian cancer molecular pathology.Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.Cellular and molecular mechanisms in cancer immune escape: a comprehensive review.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.A top-down view of the tumor microenvironment: structure, cells and signaling.Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity.Adoptive Cell Therapy in Multiple Myeloma.Dichotomous roles of TGF-β in human cancer.Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.Modeling Natural Killer Cell Targeted Immunotherapies.Cell-mediated autophagy promotes cancer cell survival.Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.Platelet-Derived Ectosomes Reduce NK Cell Function.Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer The breast tumor microenvironment alters the phenotype and function of natural killer cells Prognostic implication of CD57, CD16, and TGF-β expression in oral squamous cell carcinoma.Natural killer cells modulation in hematological malignancies.Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development.

P2860

Q26752518-CCCB6BD5-04DD-46B9-A7BB-9735701F756C Q27001052-3816A0FD-5055-4B18-9184-E406727E3030 Q28073691-E48A2C8A-9ADE-485B-BC34-C30476FF29E6 Q28390399-4F7557FA-7E74-45C9-A4CD-46B615163446 Q30408424-4A6F16E6-ED67-4F59-96A8-80A3EE961D32 Q33869781-04369612-C866-4839-BFF8-C6B432D53F31 Q34276027-95A40AEA-76E4-4C62-B79B-2D52A8A846F3 Q34831085-56DE2849-0350-4D24-8A12-A669041BD75A Q35061974-3964D529-FB1A-4B2D-B10A-43D52F8C4344 Q35131244-9A034A4F-81B5-4EE6-976F-5B6646212306 Q35157421-63425F16-A237-4A58-81DD-08AFFED3FD12 Q36024656-F3FA3C3B-C70A-40CD-A3A4-FC4F60E2A6B9 Q36110266-066E2834-7E1C-4117-879D-0B42F5B77E85 Q36629398-A738A473-9AC3-40D8-AD28-6824493F5185 Q37155165-C7A749AE-5994-4822-BCB0-A74206E5B5FF Q37178190-1200341C-7B7D-498D-B906-354846D7EE67 Q37308200-0F5A34FC-11D7-4DAC-AB2A-0028569D9B74 Q37413162-3E8B97E8-177D-489F-8F2F-D3A6DEABEA64 Q37641608-92C6FED3-CB58-4CB2-94F0-0DD9BEAD8541 Q37709365-FDD67F4E-BB6D-41E2-8AB5-9D7248EA4B9A Q37716633-5A0A980A-A653-420E-B7A7-B38E551DA002 Q38021356-465F12DD-38F9-4910-BBC3-5E06F26F8BDA Q38035301-C8292CB3-1113-438D-A41E-F4F1ADA18418 Q38170150-8057D5D1-4112-4069-8108-D87362D9CC1B Q38203261-CB7B9553-24EA-424A-AC5F-64712797FBD7 Q38233046-5A261F1A-E153-4C84-B56E-9F52874764BE Q38527867-11BFB5FE-1867-434C-9005-C85E9EB38702 Q38559350-C7DD00EB-7B21-4855-9FE3-19726CF8D11E Q38635138-8DFFF2B7-606D-4D63-A35D-C0F0CD020F6D Q39027205-C8AA4C84-3C15-462F-BCC4-97623C9381AC Q39159252-177860BC-FD5A-4E22-86BD-5E6BB070DA9B Q39239278-53C626DA-8C08-43F3-AC12-16F382C5189B Q39364287-B047B4AC-7FC3-4514-81DD-294D07F1B9D5 Q40113311-6386EF1D-B3D3-4999-A65C-C1DA4D5BC129 Q40603140-621F1F52-E0D3-4133-9AD5-4000693003FC Q41016369-A7121FD1-B088-49B1-80CE-6977090DE8AC Q41049892-6F81E419-A9D1-4308-BE0B-49A87E35682A Q41161716-172DB141-E97C-4E7B-A2D3-44F8EFD621CC Q41982546-6200B129-42D7-4F8F-B8AD-145C7F894CCF Q42317402-FEF9C360-243B-4809-981D-07D0B618B009

P2860

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

http://www.wikidata.org/entity/Q34016504

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@ast

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en-gb

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@nl

type

label

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@ast

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en-gb

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@nl

prefLabel

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@ast

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en-gb

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@nl

P1433

Q34016504-3E518B4A-70E5-48BC-916E-0E1E369DEC21

P1476

Q34016504-D0D3C317-73E6-421D-A537-635293EEABC5

P2093

Q34016504-18B2EF52-383D-4570-82FD-386F71FE7649

Q34016504-60E3A335-5754-47F8-81BB-503B976940C2

Q34016504-62147201-E991-464D-A4C5-1D7FF07F223B

Q34016504-704C40D0-EFFA-40D2-A1D6-41460E3C8CF4

Q34016504-A166F613-1205-42CC-8C28-52D2738A3C6B

P2860

Q34016504-071ED823-33A4-4E55-B767-9F0D7C481532

Q34016504-0909040F-0EC5-4D80-B613-F53DAFAC5C36

Q34016504-0A8DC9DD-82AF-4BDE-85F9-F56462C5CFC3

Q34016504-0AC2CF2C-F1F2-4800-ABE4-35194929CA1E

Q34016504-0C1B54F4-C240-4B1C-8C4D-41CB57706CB0

Q34016504-1640BE7C-2D93-4CCE-9303-5FBA3CF69623

Q34016504-25075215-964F-49A4-9B13-81C2379B8151

Q34016504-2C153A38-EA7E-46D2-B28A-A999FE7EA6F0

Q34016504-306B48EA-6DB6-4EA3-AFDB-B1D662F7EF06

Q34016504-3B11B972-72CC-415E-BBD8-CD8FFD7FB73A

P304

Q34016504-98EC0F4E-C2C7-48D0-9186-88026AA52D7C

P31

Q34016504-87B09C1F-6D93-4DE0-8EC2-3DE09C6883FD

P356

Q34016504-BEEDDF2A-4ADF-462F-BFD8-20142C6F3BB4

P407

Q34016504-F27B246A-D612-4DA3-B044-C0514EBB1078

P433

Q34016504-96CD5863-870F-4BFB-BC31-FBD3B14E0B08

P478

Q34016504-3EF2481A-90D4-4F6E-BC00-0FD426056B11

P50

Q34016504-35CAAE32-57EA-4713-9AEF-15C801B87DAB

Q34016504-7A7DB7BE-544D-43B2-9D03-A39393AA909C

P577

Q34016504-AD005FDA-8B8F-4AF7-BA89-C42F6DC4A7BE

P5875

Q34016504-12B12B68-5DCB-4509-9EBE-3DA14B629403

P698

Q34016504-D7E2ED53-7162-495B-8024-CD5194F5079B

P932

Q34016504-ADEA27FE-2EC0-4E8B-8FD3-74F9675D3D9C

P356

JOURNAL.PONE.0022842

P1433

P1476

Human tumour immune evasion vi ...... ation of anti-tumour activity.

@en

P2093

Abbie L Neilson

http://www.w3.org/2001/XMLSchema#string

Alan A Melcher

http://www.w3.org/2001/XMLSchema#string

Erica B Wilson

http://www.w3.org/2001/XMLSchema#string

Geoffrey D Hall

http://www.w3.org/2001/XMLSchema#string

Josephine L Meade

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

An activating immunoreceptor complex formed by NKG2D and DAP10

Hallmarks of Cancer: The Next Generation

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7

Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells

Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells

Non-Smad pathways in TGF-beta signaling

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Natural innate and adaptive immunity to cancer

P304

e22842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0022842

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Jehan J El-Jawhari

P577

2011-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51640804

http://www.w3.org/2001/XMLSchema#string

P698

21909397

http://www.w3.org/2001/XMLSchema#string

P932

3167809

http://www.w3.org/2001/XMLSchema#string